ChaudhryMMushtaqMD

PubMed

• 66 citations
  Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes
  Janice Gabrilove, Ronald Paquette, Roger M. Lyons, Chaudhry Mushtaq, Mikkael A. Sekeres, Dianne Tomita, Lyndah Dreiling> ;British Journal of Haematology. 2008 Aug 1
• Darbepoetin alfa for treating anemia in patients with low-risk myelodysplastic syndromes: Exploratory analysis of baseline predictors of response.
  Gabrilove J, Paquette R, Lyons R, Mushtaq C, Sekeres M, Lam H, Dreiling L> ;J. Clin. Oncol.. 2006-06-20
• Darbepoetin alfa for treating anemia in low-risk myelodysplastic syndrome patients: Interim results after 27/28 weeks.
  Paquette R, Gabrilove J, Lyons R, Mushtaq C, Sekeres M, Lam H, Dreiling L> ;J. Clin. Oncol.. 2006-06-20
• 4 citations
  A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed-dose oral etoposide in patients with solid tumors
  Caio M. S. Rocha Lima, Carlo V. Catapano M.D., Daniel Pacheco, Carol A. Sherman, Greg Oakhill, Chaudhry Mushtaq, Kimberly D. Freeman, Mark R. Green> ;Cancer. 2004 Jun 15
• Irinotecan in the management of patients with pancreatic cancer.
  Green, M. R., Harper, M., Safa, A., Sherman, C. A., Mushtaq, C. M., Bahadori, H., Brescia, F. J., Rocha Lima, C. M.> ;Oncology (Williston Park). 2000 Dec
• Join now to see all